MGFA Session 2025: Imaavy eases gMG in teens for up to 1.5 years
Treatment with Imaavy (nipocalimab-aahu) has led to sustained disease control for up to 1.5 years among adolescents with…
Articles by Lindsey Shapiro, PhD
MGFA Session 2025: Gefurulimab eases symptoms in gMG trial
Weekly treatment with gefurulimab —an investigational C5 inhibitor from Alexion, Astrazeneca Rare Disease, that’s designed to be self-administered…
MGFA Session 2025: Vyvgart eases seronegative gMG disease severity
Vyvgart (efgartigimod alfa-fcab) led to significant and clinically meaningful reductions in disease severity among adults with generalized myasthenia…
MGFA Session 2025: Vyvgart safe, effective in adolescents with gMG
Vyvgart (efgartigimod alfa-fcab), currently approved in the U.S. for treating certain adults with generalized myasthenia gravis (gMG), safely…
Efficacy prioritized in treatment of generalized myasthenia gravis
Neurologists consider the degree of clinical efficacy and the onset of action as the most important factors when making treatment…
Switch to Zilbrysq for gMG found safe, effective in clinical trial
Daily treatment with Zilbrysq (zilucoplan) was safe and effective in people with generalized myasthenia gravis (gMG) who were…
Vyvgart Hytrulo formulation available for generalized MG in US
The recently approved prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that offers the possibility of…
FDA approves J&J’s nipocalimab, now Imaavy, to treat gMG
The U.S. Food and Drug Administration (FDA) has approved nipocalimab as a treatment for adults and adolescents, ages 12…
Diverse mechanisms found for myasthenia gravis’ AChR antibodies
Disease-causing antibodies from different myasthenia gravis (MG) patients bind to and affect the function of acetylcholine receptors (AChRs) in…
Vyvgart Hytrulo prefilled syringe gets US regulatory approval
The U.S. Food and Drug Administration (FDA) has approved a version of Argenx’s Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)…